Noteworthy Price Action: Could Inovio Pharmaceuticals Inc Decline After Today’s Big Increase?

Noteworthy Price Action: Could Inovio Pharmaceuticals Inc Decline After Today's Big Increase?

The stock of Inovio Pharmaceuticals Inc (NASDAQ:INO) is a huge mover today! About 510,748 shares traded hands. Inovio Pharmaceuticals Inc (NASDAQ:INO) has declined 38.10% since April 4, 2016 and is downtrending. It has underperformed by 39.19% the S&P500.
The move comes after 7 months positive chart setup for the $471.20 million company. It was reported on Nov, 4 by Barchart.com. We have $9.69 PT which if reached, will make NASDAQ:INO worth $254.45M more.

Analysts await Inovio Pharmaceuticals Inc (NASDAQ:INO) to report earnings on November, 14. They expect $-0.27 EPS, down 485.71% or $0.34 from last year’s $0.07 per share. After $-0.26 actual EPS reported by Inovio Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 3.85% negative EPS growth.

Inovio Pharmaceuticals Inc (NASDAQ:INO) Ratings Coverage

Out of 2 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Inovio Pharmaceuticals has been the topic of 7 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Monday, March 14 by Brean Capital. The stock has “Hold” rating given by Zacks on Wednesday, August 12. The firm has “Overweight” rating given on Monday, August 10 by Piper Jaffray. Zacks downgraded Inovio Pharmaceuticals Inc (NASDAQ:INO) on Friday, August 14 to “Hold” rating. The firm has “Hold” rating given on Tuesday, August 9 by Maxim Group. Maxim Group maintained it with “Buy” rating and $23 target price in Wednesday, September 9 report. As per Tuesday, January 5, the company rating was maintained by Maxim Group.

According to Zacks Investment Research, “Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company’s electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio’s clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company’s partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.”

Another recent and important Inovio Pharmaceuticals Inc (NASDAQ:INO) news was published by Fool.com which published an article titled: “Better Buy: Juno Therapeutics vs. Inovio Pharmaceuticals” on October 28, 2016.

INO Company Profile

Inovio Pharmaceuticals, Inc. (Inovio), incorporated on June 15, 2001, is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. The Firm has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers (cervical, head and neck, and anal), prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovio’s immunotherapies consist of one or more DNA plasmids encoding one or more selected antigen that are introduced into cells of humans or animals. Inovio’s immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment